Charlotte Schubert
Lightspeed Microscopy raises $4M Series A from Dynamk Capital to commercialize 3D pathology imaging platform
Lightspeed Microscopy, a Seattle startup spun out of the University of Washington, raised $4 million in a Series A led by Dynamk Capital to commercialize an end-to-end 3D pathology microscopy platform that optically clears and rapidly scans intact samples, then uses cloud-based AI to produce 3D images for pharma and clinical use.
University of Washington-backed Seattle neighborhood delivery hub launches near Space Needle, testing electric-assist trikes and parcel lockers with Coaster Cycles, BrightDrop and AxleHire
Seattle launched its first neighborhood delivery hub near the Space Needle as a University of Washington Urban Freight Lab pilot to test last-mile logistics using electric-assist cargo trikes, parcel lockers and partnerships with companies like Coaster Cycles, BrightDrop and AxleHire. The hub aims to cut costs and emissions in the final leg of deliveries while serving as a community gathering spot.
Nautilus Biotechnology (NAUT) goes public via SPAC, raises $345 million to commercialize proteome analysis
Nautilus Biotechnology, co-founded by Sujal Patel and Parag Mallick, is going public on Nasdaq as NAUT through a SPAC merger that raised $345 million to advance a new proteome analysis platform aimed at accelerating biomedical research and drug development. Institutional backers include Bezos Expeditions, Vulcan Capital and Madrona Venture Group, and the deal closes on the 25th anniversary of Patel’s arrival in Seattle.
FDA’s accelerated approval of Biogen’s aducanumab may ease path for Seattle’s Athira Pharma as ATH-1017 advances
The FDA granted accelerated approval to Biogen’s aducanumab, the first new Alzheimer’s drug in nearly 20 years, a decision that could ease regulatory pathways for other companies like Seattle-based Athira Pharma and lifted Athira’s stock about 4%. Athira CEO Leen Kawas said the approval brings optimism as the company advances its late-stage candidate ATH-1017, a regenerative therapy targeting HGF to repair neuronal connections.
MicrobiomX raises $1M pre-seed to commercialize stool collection, processing and capsule-encapsulation device
Seattle startup MicrobiomX raised $1 million in a pre-seed round to develop a device that collects, processes and extrudes stool into capsules for clinical fecal microbiota transplantation and offers microbiome analysis services. The company, launched in 2020 from UW and Seattle Children’s Hospital research after a $50,000 CoMotion grant, aims to simplify messy current stool-processing methods used for FMT and autologous FMT.